APA (7th ed.) Citation

Li, H., Liu, Y., & Zhang, X. Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer. Elsevier.

Chicago Style (17th ed.) Citation

Li, Huikai, Yang Liu, and Xihao Zhang. Updated Efficacy and Safety Data from a Phase II, Single-arm, Open-label Study of Durvalumab Plus Gemcitabine, Cisplatin, and Nab-paclitaxel (DurGAP) In resectable Biliary Tract Cancer. Elsevier.

MLA (9th ed.) Citation

Li, Huikai, et al. Updated Efficacy and Safety Data from a Phase II, Single-arm, Open-label Study of Durvalumab Plus Gemcitabine, Cisplatin, and Nab-paclitaxel (DurGAP) In resectable Biliary Tract Cancer. Elsevier.